THE RISK AND BENEFIT OF CHEMOTHERAPY IN PATIENTS WITH STAGE IV NON-SMALL LUNG CANCER PRE-EXISTING INTERSTITIAL LUNG DISEASE

被引：0
|
作者：
Takamura, K. [1 ,2 ]
Asahina, H. [2 ]
Oizumi, S. [2 ]
Fujita, Y. [2 ]
Kojima, T. [2 ]
Harada, T. [2 ]
Kawai, Y. [2 ]
Sasaki, T. [2 ]
Yamamoto, M. [2 ]
Dosaka-Akita, H. [2 ]
Isobe, H. [2 ]
Nishimura, M. [2 ]
机构：
[1] Obihiro Kosei Gen Hosp, Dept Med 1, Obihiro, Hokkaido, Japan
[2] Hokkaido Lung Canc Clin Study Grp, Sapporo, Hokkaido, Japan
来源：
RESPIROLOGY | 2012年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：84 / 84
页数：1
相关论文
共 50 条
  • [1] Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer
    Nakanishi, Yu
    Masuda, Takeshi
    Yamaguchi, Kakuhiro
    Sakamoto, Shinjiro
    Horimasu, Yasushi
    Nakashima, Taku
    Miyamoto, Shintaro
    Tsutani, Yasuhiro
    Iwamoto, Hiroshi
    Okada, Morihito
    Hattori, Noboru
    Fujitaka, Kazunori
    Miyata, Yoshihiro
    Hamada, Hironobu
    RESPIRATORY INVESTIGATION, 2019, 57 (05) : 451 - 459
  • [2] Distinctive impact of pre-existing interstitial lung disease on the risk of chemotherapy-related lung injury in patients with lung cancer
    Ozawa, Yuichi
    Akahori, Daisuke
    Koda, Keigo
    Abe, Takefumi
    Hasegawa, Hirotsugu
    Matsui, Takashi
    Tanahashi, Masayuki
    Niwa, Hiroshi
    Yamada, Kazunari
    Yokomura, Koshi
    Suda, Takafumi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (05) : 1031 - 1038
  • [3] Distinctive impact of pre-existing interstitial lung disease on the risk of chemotherapy-related lung injury in patients with lung cancer
    Yuichi Ozawa
    Daisuke Akahori
    Keigo Koda
    Takefumi Abe
    Hirotsugu Hasegawa
    Takashi Matsui
    Masayuki Tanahashi
    Hiroshi Niwa
    Kazunari Yamada
    Koshi Yokomura
    Takafumi Suda
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 1031 - 1038
  • [4] Pre-existing interstitial lung abnormalities are independent risk factors for interstitial lung disease during durvalumab treatment after chemoradiotherapy in patients with locally advanced non-small lung cancer.
    Daido, Wakako
    Masuda, Takeshi
    Imano, Nobuki
    Matsumoto, Naoko
    Shoda, Hiroyasu
    Hamai, Kosuke
    Iwamoto, Yasuo
    Takayama, Yusuke
    Mishima, Shohei
    Masuda, Ken
    Kawase, Shigeo
    Awaya, Yoshikazu
    Nishimura, Yoshifumi
    Shiota, Naoki
    Ishikawa, Nobuhisa
    Yamasaki, Masahiro
    Kitaguchi, Soichi
    Fujitaka, Kazunori
    Nagata, Yasushi
    Hattori, Noboru
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] PRE- EXISTING INTERSTITIAL LUNG ABNORMALITIES ARE RISK FACTORS FOR IMMUNE CHECKPOINT INHIBITORINDUCED INTERSTITIAL LUNG DISEASE IN NON-SMALL CELL LUNG CANCER
    Masuda, Takeshi
    Nakanishi, Yu
    Sakamoto, Shinjiro
    Horimasu, Yasushi
    Nakashima, Taku
    Miyamoto, Shintaro
    Iwamoto, Hiroshi
    Fujitaka, Kazunori
    Hamada, Hironobu
    Hattori, Noboru
    RESPIROLOGY, 2019, 24 : 248 - 249
  • [6] Safety of topotecan monotherapy for relapsed small cell lung cancer patients with pre-existing interstitial lung disease
    Yasunori Enomoto
    Naoki Inui
    Shiro Imokawa
    Masato Karayama
    Hirotsugu Hasegawa
    Yuichi Ozawa
    Takashi Matsui
    Koshi Yokomura
    Takafumi Suda
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 499 - 505
  • [7] Safety of topotecan monotherapy for relapsed small cell lung cancer patients with pre-existing interstitial lung disease
    Enomoto, Yasunori
    Inui, Naoki
    Imokawa, Shiro
    Karayama, Masato
    Hasegawa, Hirotsugu
    Ozawa, Yuichi
    Matsui, Takashi
    Yokomura, Koshi
    Suda, Takafumi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (03) : 499 - 505
  • [8] Association of pre-existing lung interstitial changes with immune-related pneumonitis in patients with non-small lung cancer receiving immunotherapy
    Chen, Xiuqiong
    Li, Zhaona
    Wang, Xinyue
    Zhou, Jing
    Wei, Qianhui
    Jiang, Richeng
    SUPPORTIVE CARE IN CANCER, 2022, 30 (08) : 6515 - 6524
  • [9] Association of pre-existing lung interstitial changes with immune-related pneumonitis in patients with non-small lung cancer receiving immunotherapy
    Xiuqiong Chen
    Zhaona Li
    Xinyue Wang
    Jing Zhou
    Qianhui Wei
    Richeng Jiang
    Supportive Care in Cancer, 2022, 30 : 6515 - 6524
  • [10] Impact of pre-existing interstitial lung abnormal shadow on lung injury development and severity in patients of non-small cell lung cancer treated with osimertinib
    Shibaki, Ryota
    Ozawa, Yuichi
    Noguchi, Susumu
    Murakami, Yusuke
    Takase, Eri
    Azuma, Yuichiro
    Maebeya, Masaru
    Sugimoto, Takeya
    Hayata, Atsushi
    Hayakawa, Takahiro
    Tamaki, Shinya
    Nakanishi, Masanori
    Teraoka, Shunsuke
    Akamatsu, Hiroaki
    CANCER MEDICINE, 2022, 11 (20): : 3743 - 3750
12345